Hematology Frontier

Editor's Note：Acute leukemia is a group of malignant hematological diseases that pose a serious threat to human health, making its treatment a major focus of medical research. At the 2024…

From January 3–5, 2025, the 5th Annual Meeting of Chinese Alliance for Societies of Hematology (CASH) was held in Tianjin under the theme “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” The event gathered leading experts from China and abroad to discuss the latest advancements and future trends in hematology. Professor Jun Shi, Deputy Director of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences , followed up on his remarkable presentation at last year’s CASH conference with an update on lentiviral vector gene therapy for thalassemia.In this exclusive feature, Hematology Frontier invited Professor Shi to share the promising clinical results achieved by his team and outline their future research plans.

At the 5th Annual Meeting of Chinese Alliance for Societies of Hematology (2025 CASH), Professor Ying Wang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, presented a detailed summary of the latest research on CAR-T therapy for ALL. Her presentation covered the efficacy and safety of CAR-T therapies targeting various antigens, including CD19, CD22, and dual-target CAR-T approaches, as well as their application in specific patient populations. She also explored the factors influencing CAR-T therapy outcomes and discussed future directions to optimize this treatment for clinical use. Hematology Frontier has compiled the key insights from her presentation.

Published in Blood and presented at ASH 2024, the LUNA 3 study evaluates the efficacy and safety of rilzabrutinib, an oral Bruton Tyrosine Kinase Inhibitor (BTKi), in patients with previously…

Recently published in Blood, the DREPAGREFFE-2 trial provides crucial insights into long-term cognitive and cerebrovascular outcomes in children with sickle cell anemia (SCA) and a history of abnormal cerebral velocities.…

A recent study published in Blood (Volume 144, Supplement 1, November 5, 2024) explores the role of Lactate Dehydrogenase A (LDH-A) in CD8+ T cell differentiation and its impact on…

A study published in Blood on November 5, 2024, reveals how socioeconomic factors influence access to allogeneic hematopoietic cell transplantation (allo-HCT) for acute myeloid leukemia (AML) patients. The findings indicate…

Presented on November 5, 2024, new research highlights the potential of IMA001 as a novel therapeutic approach for Sickle Cell Disease (SCD). The study demonstrated that IMA001 significantly reduced red…

On December 7, 2024, a phase 3 trial published in The New England Journal of Medicine provided compelling evidence on the addition of blinatumomab to chemotherapy in children with newly…

The 66th American Society of Hematology (ASH) Annual Meeting has successfully concluded, bringing together over 30,000 experts and scholars worldwide. Through meticulously curated sessions, the conference provided profound insights into fundamental research, innovative therapies, and disease management in hematology. To highlight the latest developments, Hematology Frontier presents the News of ASH series, offering key takeaways from ASH’s official reports.